Q-omics provides the consensus-scored GAPDHP49 profile across patient tissues and cancer cell-line models. GAPDHP49 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, GAPDHP49 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, GAPDHP49 RNA expression shows 8,218 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight THCA, STAD, and LIHC as cancer lineages where GAPDHP49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP49 survival associations across molecular data types. GAPDHP49 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP49 RNA expression–survival associations across cancer types. High GAPDHP49 expression shows unfavorable associations in THCA, ACC and KICH, but favorable associations in UCS, STAD and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for GAPDHP49 RNA expression.
This table summarizes GAPDHP49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP49 shows lower tumor expression in KICH and THCA and higher tumor expression in STAD and HNSC. The STAD box plot shows higher GAPDHP49 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p = .001).
This table shows molecular features associated with GAPDHP49 in patient tissues and cancer cell lines. In patient samples, GAPDHP49 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
